STAY HOME AND STAY SAFE. For more information and support on COVID-19 please visit sacoronavirus

Why choose Ferrimed®?

Iron Polymaltose Complex (IPC), as contained in Ferrimed®, is clinically proven to be effective in the treatment of iron deficiency (ID) and iron deficiency anaemia (IDA).1,2 Trust Ferrimed®, S.A.’s #1 prescribed iron treatment.3

Several iron salts are available but can be toxic in the case of overdosage 1

Iron salts are more likely to cause unwanted side effects such as constipation, nausea, vomiting and diarrhoea.4,5
Though food would improve tolerability, iron salts (e.g., ferrous sulphate) are generally recommended to be taken on an empty stomach because food can interfere with the iron absorption from these compounds.1,2

IPC, as contained in Ferrimed®, has a favourable side effect profile & can be taken with most other medications1,4,6

IPC can be taken at any time, with or without food, and the absorption of iron will not be affected.1,2,4 In fact, studies have demonstrated that iron absorption with IPC significantly increases when taken with food.1,4 IPC, as contained in Ferrimed®, does not interact with most other medications.5
Clinical trials with IPC have shown significantly fewer side effects, such as nausea, vomiting, and heartburn than in patients taking ferrous supplements.1,2

Ferrimed® provides treatment quantities of iron

Guidelines recommend a dose of 100 to 200 mg of elemental iron daily for the treatment of ID and IDA.7—10 Iron supplements contain varying quantities of elemental iron, so it is important to check how much elemental iron you are getting with each daily dose. Ferrimed® D.S. Chewable Tablets contain 100 mg elemental iron per dose, which provides treatment quantities of iron when taken as directed. Importantly, this is an adult dose and children’s doses are calculated using body mass.
  1. Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex. Arzneimittel-Forschung 2007;57(6a):439-452.
  2. Borbolla JR, Cicero RE, Dibildox M, Sotres D, Gutiérrez R. Iron hydroxide polymaltose complex vs iron sulphate in the treatment of iron deficiency anaemia in infants. Revista Mexicana de Pediatria 2000;57(2):63-67.
  3. Ferrimed® Impact Rx. December 2022.
  4. Yasa B, Agaoglu L, Unuvar E. Efficacy, tolerability, and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: a randomized trial in pediatric patients with iron deficiency anemia. Int J Pediatr 2011;1-6.
  5. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3:12-33.
  6. Burckhardt-Herold S, Klotz J, Funk F, Büchi R, Petrig-Schaffland J, Geisser P. Interactions between iron(III)-hydroxide polymaltose complex and commonly used drugs. Arzneimittel-Forschung 2007;57(6a):360-369.
  7. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87(2):98-104.
  8. Ning S, Zeller M. Management of iron deficiency. Hematology. 2019;(1):315-322.
  9. Alli N, Vaughn J, Patel M. Anaemia: approach to diagnosis. S Afr Med J 2017;107(1):23-27.
  10. Goddard AF, James MW, McIntyre AS, Scott BB on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 2011;60:1309-1316.
Ferrimed® is a registered trademark of CSL Vifor Pharma Group and is used under licence. © 2023 Aspen Group of companies or its licensor. All rights reserved. Marketed by Pharmacare Limited t/a Aspen Pharmacare. Co. Reg. No. 1898/000252/06 Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-IFF-08-22-00002. 03/2023.
ID and IDA need to be confirmed by laboratory tests.
www.aspenpharma.com | 0800 122 912
Copyright © 2023 Ferrimed. All rights reserved.